Hidekazu Yamada

Natori-shi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

The iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation models.

The iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation models.

Journal: The Journal of biological chemistry

Published: October 10, 2025

FDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cells.

FDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cells.

Journal: The Journal of biological chemistry

Published: April 17, 2024

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.

Journal: Nature communications

Published: April 18, 2023

Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125.

Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125.

Journal: Gynecologic oncology reports

Published: June 08, 2021

Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.

Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.

Journal: FEBS letters

Published: September 03, 2019

Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms.

Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms.

Journal: Journal of gynecologic oncology

Published: August 30, 2019

Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological Cancer.

Pelvic Exenteration as Potential Cure and Symptom Relief in Advanced and Recurrent Gynaecological Cancer.

Journal: Anticancer research

Published: July 28, 2019

Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer.

Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer.

Journal: Molecular and clinical oncology

Published: April 26, 2019

Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D -driven tumor promotion.

Loss of protein phosphatase 6 in mouse keratinocytes enhances K-rasG12D -driven tumor promotion.

Journal: Cancer science

Published: February 09, 2018

Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.

Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.

Journal: Japanese journal of clinical oncology

Published: January 08, 2018

Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.

Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.

Journal: International journal of clinical oncology

Published: October 05, 2016

Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.

Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.

Journal: International journal of clinical oncology

Published: September 29, 2015

Showing 1-12 of 17

Last Updated: 09/26/2026